News
We provide the latest news from the world of economics and finance
We provide the latest news from the world of economics and finance
(RTTNews) - G1 Therapeutics, Inc. (GTHX) Monday said its Phase 3 PRESERVE 2 study evaluating trilaciclib administered prior to chemotherapy in patients with metastatic triple negative breast cancer (mTNBC) did not meet primary goal of overall survival (OS).
The median OS was 17.4 months in people who were treated with trilaciclib plus chemotherapy compared to 17.8 months in patients who did not receive the therapy.
G1 said it plans to wind down the Phase 3 PRESERVE 2 trial.
The company expects to generate revenue between $60 million and $70 million from its Cosela in 2024. G1 added that it is sufficiently funded to achieve profitability in the second half of 2025.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
© 2024 Lime Trading (CY) Ltd
Lime Trading (CY) Ltd is authorised and regulated by the Cyprus Securities and Exchange Commission in accordance with license No.281/15 issued on 25/09/2015. The "Just2Trade" trademark is owned by LimeTrading (CY) Ltd.
Registration Number: HE 341520
Address: Lime Trading (CY) Ltd
Magnum Business Center, Office 4B, Spyrou Kyprianou Avenue 78
Limassol 3076, Cyprus
Disclaimer:
All promotions, materials and information of this website may have applied conditions. Please contact the Company for further details
Trading on financial markets carries risks. The value of the investments can both increase and decrease and the investors may lose all their investment capital. In case of a leveraged product, the loss may be more than the initial capital invested. Detailed information on risks associated with trading on financial markets can be found in General Terms and Conditions for the Provision of Investment Services.
E-mail: 24_support@just2trade.online
